問卷

TPIDB > Search Result

Search Result

篩選

List

5239Cases

2016-03-07 - 2020-02-26

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2016-04-16 - 2018-08-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2013-11-29 - 2013-11-29

Phase II

A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients.
  • Condition/Disease

    Common Warts / Verruca Vulgaris (CWs)

  • Test Drug

    SR-T100

Participate Sites
4Sites

Study ended4Sites

2017-01-01 - 2020-06-30

Phase II

A Randomized, Double-Blind, Vehicle-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F703 GEL in Subjects with Diabetic Foot Ulcers
  • Condition/Disease

    Diabetic foot ulcers,DFUs

  • Test Drug

    ENERGI-F703 GEL

Participate Sites
7Sites

Terminated7Sites

2017-01-17 - 2021-12-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2017-06-08 - 2019-04-30

Phase II

An Open-Label, Phase II Study to Evaluate the Efficacy and Safety of SCB01A in Subjects with Recurrent or Metastatic Squamous Cell Head and Neck Cancer Who Have Failed Platinum-Based Treatment
  • Condition/Disease

    Squamous Cell Head and Neck Cancer

  • Test Drug

    SCB01A

Participate Sites
4Sites

Terminated4Sites

張牧新
Taipei Veterans General Hospital

Division of Hematology & Oncology

夏和雄
Taipei Medical University Hospital

Division of Hematology & Oncology

2018-03-01 - 2020-02-29

Phase II

A Randomized, Double-Blind, Active-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F701 Solution in Female Subjects with Hair Loss
  • Condition/Disease

    Hair Loss

  • Test Drug

    ENERGI-F701

Participate Sites
2Sites

Recruiting1Sites

Terminated1Sites

2014-01-01 - 2018-07-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2009-06-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated1Sites

Study ended4Sites

2009-11-01 - 2011-08-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Study ended3Sites